Researchers from Sant Pau have published an article in Frontiers in Medicine (journal of the first quartile of the Internal Medicine area) where they analyse the incidence and predictive factors of pulmonary embolisms or thrombosis in patients hospitalised with Covid-19. The research has concluded that the incidence of 2.6% of pulmonary embolisms or thrombosis in patients hospitalized with Covid-19 is clearly high.
This study involved professionals from the Sant Pau Internal Medicine, Haematology, Pneumology, Radiology and Rheumatology Services who were collecting data from patients admitted to the Hospital with Covid-19 during the pandemic, between 9 March and 15 April.
The research has concluded that the incidence of 2.6% of pulmonary embolism or thrombosis in patients hospitalized with Covid-19 is clearly high. Considering that most patients were already receiving thromboprophylaxis, the possibility of administering higher doses of thromboprophylaxis to prevent embolism and pulmonary thrombosis, especially in patients at higher risk, is assessed. In this regard, the study identifies that the patients at greatest risk are those who arrive with high levels of C-reactive protein and D-dimer on admission.
The researchers suggest the validation of the results with further studies. Additionally, the data suggest that pulmonary thrombosis may be related to the development of the most severe cases of Covid-19.
Team: David Filella, Natividad Benito, Jose Mateo , Ana M. Fortuna, Juan E. Gutiérrez-Alliende, Nerea Hernández , Ana M. Gimenez, Virginia Pomar, Ivan Castellví, Héctor Corominas, Jordi Casademont and Pere Domingo.
